Biotek-snakken — Juni 2020
-
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Chiasma to $22 from $13 and reiterates an Overweight rating on the shares after the FDA approved Mycapssa, the first and only oral therapy for the treatment of acromegaly. The analyst sees "significant" demand for an oral therapy from acromegaly patients who he notes currently receive "painful" monthly injections and often experience break-through symptoms and insufficient coverage.
-
Cantor Fitzgerald analyst Brandon Folkes maintained an Overweight rating and $18 price target on Chiasma. The analyst said that the FDA approval for Mycapssa for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide is a "giant leap" for Chiasma. He sees Mycapssa, as the only approved oral octreotide, gaining meaningful share in the market once launch in Q4.
-
-
Test
-
-
HRTX fik et CRL fra FDA - aktien falder 28% øv. https://finance.yahoo.com/news/heron-therapeutics-receives-complete-response-124500540.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind